Reported 3 days ago
Certara Inc. (NASDAQ:CERT) experienced a remarkable 35.18% increase in share prices last week, closing at $12.91, attributed to the launch of its new Simcyp Simulator supporting physiologically-based pharmacokinetic (PBPK) modeling. This advancement solidifies Certara's leadership in drug development and regulatory decision-making. The company also reported a significant turnaround with a net income of $6.6 million in Q4 2024, alongside a projected revenue range of $415 million to $425 million for the year.
Source: YAHOO